Trigeminal Neuralgia Study

Background

Biohaven Pharmaceuticals is studying rimegepant, for the treatment of Trigeminal Neuraligia (TN). If you are 18 years or older and suffer from TN, you may qualify. 

This is a Phase 2 multi-center clinical trial to evaluate the safety and efficacy of Rimegepant compared to placebo for subjects with Trigeminal Neuralgia. Placebo is inactive substance and does not contain any study medication.

​Health insurance is not required to take part in this study and compensation for participation may also be provided. 

TN Study Details

This is a 7-9 week study which will require several clinic visits. Patients will receive both active medication (rimegepant) and placebo.​

Why Participate?

By joining this study, you will help contribute to our understanding of this disorder and the potential effectiveness of rimegepant for the treatment of TN. You will also receive:

  • Study-related evaluations of your TN-related symptoms and overall health.
  • Investigational drug and study-related care at no cost to you.
  • You may receive compensation for your participation

Learn More

Tags for this post
Share on facebook
Share on email
Share on twitter

Subscribe

Signup for relevant content in your inbox.

Learn

Browse Recent Articles

View or Download the Patient Guide

Learn more about neuropathic facial pain, including how to get a diagnosis, treatments, and more by viewing or downloading our free patient guide.

By filling out the form below, you will receive a free FPA Patient Guide and periodic updates on the management and treatment of facial pain conditions. We do not share this information with any outside sources.

By filling out the form below, you will receive a free FPA Patient Guide and periodic updates on the management and treatment of facial pain conditions. We do not share this information with any outside sources.